Breaking Through Cancer Pain: From Single‐Drug Management to Multimodal Analgesia
Pain Research and Management · 2026-01 · 2026 (1)
DOI: 10.1155/prm/5161889 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pain Research and Management, online erschienen am 31.07.2026. Verfasst von Yating Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese, Medical University, Huzhou, Zhejiang, China, gumed.edu.pl. Hauptthemen laut MEDLINE: Cancer Pain, Pain Management, Analgesics, Analgesia. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, Key Laboratory for NeuroInformation of Ministry of Education.
Abstract (Originalsprache)
Background
Cancer pain affects 60%–80% of patients with advanced cancer, and approximately 30% of patients experience inadequate pain control. Although the World Health Organization (WHO) three‐step analgesic ladder has substantially improved pain management, inadequate analgesia, opioid‐related adverse effects, and refractory pain continue to pose significant clinical challenges.
Objective
This narrative review critically evaluates recent advances in cancer pain management, including novel analgesics, optimized opioid formulations, nanomedicine, invasive interventions (intrathecal drug delivery, neuromodulation, and neurolysis), and complementary integrative therapies, aiming to provide up‐to‐date insights for clinicians and researchers.
Results
Novel analgesics targeting μ‐opioid receptor bias, ion channels, and multitarget strategies have shown preclinical promise. Improved opioid formulations and nanomedicine‐based approaches may enhance drug delivery and reduce toxicity. Fourth‐step interventions, including intrathecal drug delivery, neuromodulation, and neurolysis, provide targeted options for selected patients with refractory cancer pain. Integrative therapies, including mind–body interventions, acupuncture, massage, music therapy, and game‐based approaches, may improve symptom burden and quality of life, although evidence for direct analgesic effects remains limited.
Conclusion
Cancer pain management is evolving toward a multimodal and increasingly personalized framework. Despite substantial progress, many emerging therapies lack robust cancer‐specific validation. High‐quality clinical trials, standardized treatment protocols, and improved translational strategies are needed to establish evidence‐based precision cancer pain management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese, Medical University, Huzhou, Zhejiang, China, gumed.edu.pl.
- Huzhou Central Hospital, Affiliated Central Hospital, Huzhou Normal University, Huzhou, Zhejiang, China, hzhospital.com.
- Zhejiang-France United Laboratory of Integrated Traditional Chinese and Modern Medicine in Colorectal Cancer, Huzhou, Zhejiang, China.
- College of Information Engineering, Huzhou Normal University, Huzhou, Zhejiang, China.
ORCID-Profile: Yating Xu, Shu Xu, Bo Huang, Zefeng Wang, He Liu, Jing Zhuang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Key Laboratory for NeuroInformation of Ministry of Education
- Zhejiang Province Cerebrovascular Disease Diagnosis and Treatment of Traditional Chinese Medicine Multidisciplinary Innovation Team Project
- "Integration of Medicine, Industry and Information" Collaborative Innovation Center Fund of Yangtze Delta Region
Zitieren
APA
Xu, Y., Xu, S., Huang, B., Wang, Z., Liu, H., & Zhuang, J. (2026). Breaking Through Cancer Pain: From Single‐Drug Management to Multimodal Analgesia. Pain Research and Management, 2026(1). https://doi.org/10.1155/prm/5161889
Vancouver
Xu Y, Xu S, Huang B, Wang Z, Liu H, Zhuang J. Breaking Through Cancer Pain: From Single‐Drug Management to Multimodal Analgesia. Pain Research and Management. 2026;2026(1). doi:10.1155/prm/5161889
BibTeX
@article{Xu2026,
author = {Xu, Yating and Xu, Shu and Huang, Bo and Wang, Zefeng and Liu, He and Zhuang, Jing},
title = {Breaking Through Cancer Pain: From Single‐Drug Management to Multimodal Analgesia},
journal = {Pain Research and Management},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/prm/5161889}
}
EUVIMED